ALK and non-small cell lung carcinoma: Alectinib, a second-generation ALK tyrosine kinase inhibitor (TKI), has demonstrated notable efficacy in patients with ALK-rearranged NSCLC, including those resistant to the first-generation ALK inhibitor crizotinib [5].